Alector’s Robert Paul becomes CEO at Nine Square
Plus Smeal joins Cardiff as CSO and updates from GHIT, Aclaris, Iovance, Pyramid, SomaLogic and more
Apple Tree Partners-backed Nine Square Therapeutics Inc. named Robert Paul as CEO. Paul was most recently CMO at Alector Inc. (NASDAQ:ALEC), before which he held leadership roles at Genentech Inc. for seven years. Nine Square is developing small molecules using computation and imaging for movement disorders like Parkinson’s disease and amyotrophic lateral sclerosis.
Cardiff Oncology Inc. (NASDAQ:CRDF), which is developing therapies for KRAS-mutated solid tumors, hired Tod Smeal as CSO and Charles Monahan as SVP of regulatory affairs. Smeal was CSO at Hexagon Bio Inc., CSO of cancer biology at Eli Lilly and Co. (NYSE:LLY) and director of the oncology research unit at Pfizer Inc. (NYSE:PFE). Monahan was global head of regulatory affairs for Erytech Pharma S.A. (NASDAQ:ERYP; Euronext:ERYP)...